MacroGenics, Inc. (MGNX) vs Niagen Bioscience, Inc. (NAGE)

MacroGenics, Inc. and Niagen Bioscience, Inc. are both Biotechnology companies. MacroGenics, Inc. and Niagen Bioscience, Inc. are of similar size ($242.1M and $238.2M). MacroGenics, Inc. has negative trailing earnings, so its P/E is not meaningful; Niagen Bioscience, Inc. trades at 15.2×. MacroGenics, Inc. grew revenue faster over the last twelve months: 21.9% against 11.0%. Niagen Bioscience, Inc. has the higher net margin (12.4% vs −7.97%) and the higher return on invested capital (42.0% vs 0.00%). Across the 17 metrics below, Niagen Bioscience, Inc. leads on 13 and MacroGenics, Inc. on 4.

Valuation

Metric MGNX NAGE Biotechnology median
P/E n/m 15.20 7.88
P/S 1.30 1.87 11.47
P/B 5.55 2.92 2.52
Price to free cash flow n/m 21.05 21.16
EV/EBITDA n/m 15.14 0.74
EV/Sales 0.39 1.36 10.73
Earnings yield (5.88%) 6.58% (28.84%)
Free cash flow yield (27.55%) 4.75% (23.03%)

Profitability

Metric MGNX NAGE Biotechnology median
Gross margin 78.07% 64.24% 65.16%
Operating margin (18.73%) 8.21% 0.00%
Net margin (7.97%) 12.39% 0.00%
Free cash flow margin (35.80%) 8.89% 0.00%
Return on equity (32.61%) 21.80% (57.72%)
Return on assets (4.94%) 16.14% (49.22%)
Return on invested capital 0.00% 41.95% 0.00%

Growth

Metric MGNX NAGE Biotechnology median
Revenue growth (TTM) 21.93% 10.99% 5.64%
EPS growth (last fiscal year) (10.28%) 81.82% —
Revenue growth, 5-year CAGR 7.35% 16.91% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric MGNX NAGE Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 2.96 6.50 4.73
Net debt to EBITDA 2.82 (3.80) 0.96

Dividend

Metric MGNX NAGE Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric MGNX NAGE Biotechnology median
Market cap 242.06m 238.17m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack